Background：Secukinumab Cosentyx is a fully human IgG1/κ-class monoclonal antibody mAb composed of 215 light chain amino acids and 457 heavy chain amino acids. It was discovered and developed by Novartis with the developmental name AIN457, for the treatment of uveitis, rheumatoid arthritis, ankylosing spondylitis, and psoriasis. It is produced in Chinese Hamster Ovary CHO cells using recombinant DNA technology.
